Meta-analysis reveals gut microbiota types and therapeutic targets in metabolic-associated fatty liver disease, suggesting new treatment approaches.
This study elucidated the connections between species-level gut microbiota and MAFLD, highlighting the interplay between microbiota, metabolites, and disease pathogenesis. These findings provide novel insights into the potential therapeutic targets for MAFLD.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: